IDH1 and acute myeloid leukemia: Ivosidenib is a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor that is clinically used to treat patients with relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutation [17,18].